

## Supplementary Figures/Tables

### Effects of Renal Impairment on the Pharmacokinetics of Once-Daily Amantadine Extended-Release Tablets

*CNS Drugs*

Tina deVries, PhD<sup>1</sup>; Angela Dentiste, MBA<sup>1</sup>; Clifford Di Lea, RPh, PharmD<sup>2</sup>; Vincent Pichette, MD, PhD<sup>3</sup>; David Jacobs, MD, MBA<sup>1</sup>

<sup>1</sup>Osmotica Pharmaceutical US LLC, Bridgewater, NJ, USA

<sup>2</sup>Aclairo Pharmaceutical Development Group, Inc., Vienna, VA, USA

<sup>3</sup>Hôpital Maisonneuve-Rosemont, Montreal, Quebec, Canada

Corresponding Author:

David Jacobs, MD, MBA

Osmotica Pharmaceutical US LLC

400 Crossing Boulevard, Bridgewater, NJ 08807

Tel: 1-908-809-1364


Email: [djacobs@osmotica.com](mailto:djacobs@osmotica.com)

**Supplementary Table 1.** Simulated steady state model independent PK parameters for subjects with varied CrCl receiving 129-mg amantadine ER tablet every  $\tau$  hours

$\tau$ h	CrCl (mL/min)	$C_{avg}$ (ng/mL)
24	158	300
	114	415
	90	526
48	90	263
	75	315
	60	394
72	60	263
	45	350
	30	525
96	45	263
	30	394
	22	537
120	30	315
	22	429
	15	625
168	15	447


$\tau$ , dose interval;  $C_{avg}$ , average steady state plasma concentration during a dose interval; CrCl, creatinine clearance; ER, extended-release; PK, pharmacokinetic.

**Supplementary Figure 1. Study design**



ER, extended-release.

**Supplementary Figure 2.** Relationship between amantadine renal clearance and eGFR following a single oral dose of 129-mg amantadine ER tablets in subjects with moderate or severe renal impairment and normal renal function



CLr, renal clearance; eGFR, estimated glomerular filtration rate; ER, extended-release.